The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment

Growth Hormone and IGF Research

Volumn 19, Issue 3, 2009, Pages 245-251

  Roemmler, J ^a   Steffin, B ^a   Gutt, B ^b   Sievers, C ^c   Bidlingmaier, M ^a   Schopohl, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Acromegaly; Acute effect; Combined medical treatment; Endogenous GH; Growth hormone receptor antagonist; Somatostatin analogue

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PEGVISOMANT;

ACROMEGALY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; INSULIN BLOOD LEVEL; MALE; MEAL; MONOTHERAPY; PRIORITY JOURNAL;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; MALE; MIDDLE AGED; OCTREOTIDE;

EID: 67349136837     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.11.002     Document Type: Article

References (29)

1. Holdaway I.M., and Rajasoorya C. Epidemiology of acromegaly. Pituitary 2 (1999) 29-41
2. Bevan J.S. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab. 90 (2005) 1856-1863
3. Freda P.U., Katznelson L., van der Lely A.J., Reyes C.M., Zhao S., and Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 90 (2005) 4465-4473
4. Racine M.S., and Barkan A.L. Medical management of growth hormone-secreting pituitary adenomas. Pituitary 5 (2002) 67-76
5. Melmed S., Casanueva F., Cavagnini F., et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 153 (2005) 737-740
6. Chanson P., Boerlin V., Ajzenberg C., et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin. Endocrinol. (Oxf.) 53 (2000) 577-586
7. Koop B.L., Harris A.G., and Ezzat S. Effect of octreotide on glucose tolerance in acromegaly. Eur. J. Endocrinol. 130 (1994) 581-586
8. Thorner M.O., Strasburger C.J., Wu Z., et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J. Clin. Endocrinol. Metab. 84 (1999) 2098-2103
9. van der Lely A.J., Hutson R.K., Trainer P.J., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358 (2001) 1754-1759
10. Trainer P.J., Drake W.M., Katznelson L., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 342 (2000) 1171-1177
11. Feenstra J., de Herder W.W., and ten Have S.M. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365 (2005) 1644-1646
12. van der Lely A.J., Muller A., Janssen J.A., et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J. Clin. Endocrinol. Metab. 86 (2001) 478-481
13. Jorgensen J.O., Feldt-Rasmussen U., Frystyk J., et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 90 (2005) 5627-5631
14. Neggers S.J., van Aken M.O., Janssen J.A., Feelders R.A., de Herder W.W., and van der Lely A.J. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 92 (2007) 4598-4601
15. Bristow A.F., Gooding R.P., and Das R.E. The international reference reagent for insulin-like growth factor-I. J. Endocrinol. 125 (1990) 191-197
16. Elmlinger M.W., Kuhnel W., Weber M.M., and Ranke M.B. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin. Chem. Lab. Med. 42 (2004) 654-664
17. Muller A.F., Janssen J.A., Hofland L.J., et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J. Clin. Endocrinol. Metab. 86 (2001) 590-593
18. Veldhuis J.D., Bidlingmaier M., Anderson S.M., Evans W.S., Wu Z., and Strasburger C.J. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J. Clin. Endocrinol. Metab. 87 (2002) 5737-5745
19. Karavitaki N., Botusan I., Radian S., Coculescu M., Turner H.E., and Wass J.A. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin. Endocrinol. (Oxf.) 62 (2005) 282-288
20. Paisley A.N., Hayden K., Ellis A., Anderson J., Wieringa G., and Trainer P.J. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur. J. Endocrinol. 156 (2007) 315-319
21. Schusdziarra V., and Schmid R. Physiological and pathophysiological aspects of somatostatin. Scand. J. Gastroenterol. Suppl. 119 (1986) 29-41
22. Kopchick J.J., Parkinson C., Stevens E.C., and Trainer P.J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 23 (2002) 623-646
23. Barkan A.L., Burman P., Clemmons D.R., et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J. Clin. Endocrinol. Metab. 90 (2005) 5684-5691
24. Rose D.R., and Clemmons D.R. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm. IGF Res. 12 (2002) 418-424
25. Drake W.M., Rowles S.V., Roberts M.E., et al. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol. 149 (2003) 521-527
26. De Marinis L., Bianchi A., Fusco A., et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary (2007)
27. Colao A., Ferone D., Lastoria S., et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 81 (1996) 2356-2362
28. de Herder W.W., Taal H.R., Uitterlinden P., Feelders R.A., Janssen J.A., and van der Lely A.J. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur. J. Endocrinol. 153 (2005) 67-71
29. Lamberts S.W., Uitterlinden P., Schuijff P.C., and Klijn J.G. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clin. Endocrinol. (Oxf.) 29 (1988) 411-420